Cue Biopharma Inc EV/EBIT
What is the EV/EBIT of Cue Biopharma Inc?
The EV/EBIT of Cue Biopharma Inc is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Cue Biopharma Inc
What does Cue Biopharma Inc do?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Companies with ev/ebit similar to Cue Biopharma Inc
- Carpinienne de Participations has EV/EBIT of N/A
- Efficacious Elk Capital has EV/EBIT of N/A
- Extraction Oil & Gas has EV/EBIT of N/A
- Kiromic BioPharma has EV/EBIT of N/A
- Gold State Resources has EV/EBIT of N/A
- 2760 has EV/EBIT of N/A
- Cue Biopharma Inc has EV/EBIT of N/A
- Cannabis Growth Opportunity has EV/EBIT of N/A
- Pivotal has EV/EBIT of N/A
- Entheon Biomedical has EV/EBIT of N/A
- Vinco Ventures has EV/EBIT of N/A
- AquaBounty Technologies Inc has EV/EBIT of N/A
- Walcott Resources has EV/EBIT of N/A